Camargo Pharmaceutical Services acquires Paidion Research Posted Mar 02, 2021
CINCINNATI, Ohio Camargo Pharmaceutical Services, LLC, a leading drug development and commercial partner, announced today it will acquire Paidion Research, Inc., a global pediatric clinical research organization (CRO) based in Durham, N.C.
The acquisition is the second in a continuing effort by Camargo to expand services in order to provide leading integrated solutions tailored to the needs of emerging biopharma companies addressing unmet medical needs in rare and complex areas.
“Half of all patients affected by a rare disease are children,” said Camargo CEO, Dan Duffy. “Pediatric research is critical to success as we work to deliver a comprehensive solution to emerging biopharma companies with specialized needs. We are proud to partner with the Paidion team, who have earned their reputation as the leader in pediatric clinical research.”